Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease

Publication date

2025-09

Authors

Schuitema, Pauline C E
Visseren, Frank L.J.ISNI 0000000389493675
Nordestgaard, Børge G
Teraa, MartinORCID 0000-0002-6751-6752ISNI 0000000395201798
van der Meer, Manon G
Ruigrok, Ynte M.ORCID 0000-0002-5396-2989ISNI 0000000389818257
Onland-Moret, N. CharlotteORCID 0000-0002-2360-913XISNI 0000000392818805
Koopal, C.
UCC-SMART Study Group

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

BACKGROUND AND AIMS: Despite optimal management of low-density lipoprotein cholesterol (LDL-C), substantial residual cardiovascular risk persists in patients with cardiovascular disease (CVD), which may be attributed to other atherogenic lipoproteins. We tested the hypotheses that elevated triglycerides (TGs) are related to higher residual CVD and mortality risk in patients with established CVD, and that such relationships depend on guideline-recommended lipid target achievement, high-density lipoprotein cholesterol (HDL-C) levels, and intensity of lipid-lowering therapy (LLT). METHODS: In a prospective cohort study of 9436 patients with manifest CVD, the relationships between log-transformed TG levels and recurrent cardiovascular events and all-cause mortality were analyzed overall using Cox regression models. Subsequently, analyses were stratified by achievement of low-density lipoprotein cholesterol (LDL-C) and non-HDL-C treatment goals, HDL-C levels, and LLT intensity. RESULTS: During a median follow-up of 9.0 years (IQR 4.5-14.1), 2075 recurrent cardiovascular events, 736 myocardial infarctions, 586 strokes, 1231 cardiovascular deaths, and 2729 all-cause deaths occurred. Per 1-unit higher log-TG level, the hazard ratio was 1.17 (95 % CI: 1.07-1.28) for recurrent cardiovascular events, 1.34 (1.16-1.56) for myocardial infarction, 1.10 (0.92-1.30) for stroke, 1.23 (1.09-1.38) for cardiovascular mortality, and 1.12 (1.03-1.21) for all-cause mortality. These hazard ratios did not depend on achievement of LDL-C and non-HDL-C treatment goals, HDL-C levels, or LLT intensity (all p for interaction ≥0.05). CONCLUSIONS: Elevated TGs are related to higher residual CVD and mortality risk in patients with established CVD. These relationships were unrelated to guideline-recommended lipid target achievement, HDL-C levels, and LLT intensity.

Keywords

Cardiovascular disease, Lipid targets, Lipid-lowering therapy, Residual cardiovascular risk, Secondary prevention, Triglycerides, Cardiology and Cardiovascular Medicine

Citation

Schuitema, P C E, Visseren, F L J, Nordestgaard, B G, Teraa, M, van der Meer, M G, Ruigrok, Y M, Onland-Moret, N C, Koopal, C & UCC-SMART Study Group 2025, 'Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease', Atherosclerosis, vol. 408, 120411. https://doi.org/10.1016/j.atherosclerosis.2025.120411